Detalhe da pesquisa
1.
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Nature
; 571(7766): E10, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270456
2.
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Nature
; 553(7686): 91-95, 2018 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29160310
3.
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.
Mol Cell
; 59(6): 904-16, 2015 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26344096
4.
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Mol Cancer
; 20(1): 100, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34353330
5.
Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer.
Mol Cancer
; 20(1): 58, 2021 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785037
6.
Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression.
Mol Ther
; 28(11): 2473-2487, 2020 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32592689
7.
The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Int J Cancer
; 146(2): 475-486, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31107971
8.
Synthesis of Chiral Triarylmethanes Bearing All-Carbon Quaternary Stereocenters: Catalytic Asymmetric Oxidative Cross-Coupling of 2,2-Diarylacetonitriles and (Hetero)arenes.
Angew Chem Int Ed Engl
; 59(8): 3053-3057, 2020 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31960543
9.
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Mol Cancer
; 18(1): 170, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31771591
10.
Ligand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs.
Int J Mol Sci
; 17(7)2016 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27428963
11.
Structure-Based Drug Design of Small Molecule Peptide Deformylase Inhibitors to Treat Cancer.
Molecules
; 21(4): 396, 2016 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27023495
12.
A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
Prostate
; 75(6): 653-61, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25597901
13.
Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment.
Eur J Med Chem
; 264: 116025, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38086189
14.
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
J Med Chem
; 67(9): 7283-7300, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38676656
15.
E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies.
Front Immunol
; 14: 1226057, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37497216
16.
Cell-free DNA in the management of prostate cancer: Current status and future prospective.
Asian J Urol
; 10(3): 298-316, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37538150
17.
Robotic-assisted versus laparoscopic radical prostatectomy for prostate cancer: the first separate systematic review and meta-analysis of randomised controlled trials and non-randomised studies.
Int J Surg
; 109(5): 1350-1359, 2023 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37070788
18.
Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cells.
Cancer Med
; 12(11): 12581-12592, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37039264
19.
Comprehensive analysis of the prognosis and immune infiltration of TMC family members in renal clear cell carcinoma.
Sci Rep
; 13(1): 11668, 2023 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37468683
20.
Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC.
J Med Chem
; 66(10): 6849-6868, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141440